Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024 — Oct 9th, 2024

Company estimates $51 million of milestone expense in the third quarter JERSEY CITY, N.J., October 09, 2024--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its third quarter 2024 financial results on October 31, 2024, prior...

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11 — Sep 30th, 2024

SHANGHAI, China & JERSEY CITY, N.J., September 30, 2024--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Perjeta® (pertuzumab) biosimilar HLX11 met the primary endpoint. In 2022...

Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner — Oct 9th, 2024

Organon (OGN) has been on a downward spiral lately with significant selling pressure. After declining 9.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the com...

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024 — Oct 9th, 2024

Company estimates $51 million of milestone expense in the third quarter JERSEY CITY, N.J., October 09, 2024--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its third quarter 2024 financial results on October 31, 2024, prior...

Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner — Oct 9th, 2024

Organon (OGN) has been on a downward spiral lately with significant selling pressure. After declining 9.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the com...

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024 — Oct 9th, 2024

Company estimates $51 million of milestone expense in the third quarter JERSEY CITY, N.J., October 09, 2024--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its third quarter 2024 financial results on October 31, 2024, prior...

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11 — Sep 30th, 2024

SHANGHAI, China & JERSEY CITY, N.J., September 30, 2024--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Perjeta® (pertuzumab) biosimilar HLX11 met the primary endpoint. In 2022...

Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada — Sep 26th, 2024

This World Contraception Day, organizations partner to raise awareness of the need to reduce barriers to contraception and invite others to support universal access KIRKLAND, QC and EDMONTON, AB, Sept. 26, 2024 /CNW/ - In recognition of World Contraception Day (WCD) on September 26, Org...

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands — Oct 8th, 2024

Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women...

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11 — Sep 30th, 2024

SHANGHAI, China & JERSEY CITY, N.J., September 30, 2024--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Perjeta® (pertuzumab) biosimilar HLX11 met the primary endpoint. In 2022...

Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner — Oct 9th, 2024

Organon (OGN) has been on a downward spiral lately with significant selling pressure. After declining 9.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the com...

Are Options Traders Betting on a Big Move in Organon (OGN) Stock? — Sep 25th, 2024

Investors in Organon & Co. OGN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $2.50 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows ho...

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands — Oct 8th, 2024

Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women...

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024 — Oct 9th, 2024

Company estimates $51 million of milestone expense in the third quarter JERSEY CITY, N.J., October 09, 2024--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its third quarter 2024 financial results on October 31, 2024, prior...

Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner — Oct 9th, 2024

Organon (OGN) has been on a downward spiral lately with significant selling pressure. After declining 9.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the com...

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024 — Oct 9th, 2024

Company estimates $51 million of milestone expense in the third quarter JERSEY CITY, N.J., October 09, 2024--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its third quarter 2024 financial results on October 31, 2024, prior...

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands — Oct 8th, 2024

Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women...

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11 — Sep 30th, 2024

SHANGHAI, China & JERSEY CITY, N.J., September 30, 2024--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Perjeta® (pertuzumab) biosimilar HLX11 met the primary endpoint. In 2022...

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11 — Sep 30th, 2024

SHANGHAI, China & JERSEY CITY, N.J., September 30, 2024--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Perjeta® (pertuzumab) biosimilar HLX11 met the primary endpoint. In 2022...

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11 — Sep 30th, 2024

SHANGHAI, China & JERSEY CITY, N.J., September 30, 2024--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Perjeta® (pertuzumab) biosimilar HLX11 met the primary endpoint. In 2022...

Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner — Oct 9th, 2024

Organon (OGN) has been on a downward spiral lately with significant selling pressure. After declining 9.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the com...

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands — Oct 8th, 2024

Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women...

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024 — Oct 9th, 2024

Company estimates $51 million of milestone expense in the third quarter JERSEY CITY, N.J., October 09, 2024--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its third quarter 2024 financial results on October 31, 2024, prior...

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11 — Sep 30th, 2024

SHANGHAI, China & JERSEY CITY, N.J., September 30, 2024--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Perjeta® (pertuzumab) biosimilar HLX11 met the primary endpoint. In 2022...

Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada — Sep 26th, 2024

This World Contraception Day, organizations partner to raise awareness of the need to reduce barriers to contraception and invite others to support universal access KIRKLAND, QC and EDMONTON, AB, Sept. 26, 2024 /CNW/ - In recognition of World Contraception Day (WCD) on September 26, Org...

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024 — Oct 9th, 2024

Company estimates $51 million of milestone expense in the third quarter JERSEY CITY, N.J., October 09, 2024--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its third quarter 2024 financial results on October 31, 2024, prior...

Are Options Traders Betting on a Big Move in Organon (OGN) Stock? — Sep 25th, 2024

Investors in Organon & Co. OGN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $2.50 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows ho...

Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner — Oct 9th, 2024

Organon (OGN) has been on a downward spiral lately with significant selling pressure. After declining 9.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the com...

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands — Oct 8th, 2024

Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women...

Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada — Sep 26th, 2024

This World Contraception Day, organizations partner to raise awareness of the need to reduce barriers to contraception and invite others to support universal access KIRKLAND, QC and EDMONTON, AB, Sept. 26, 2024 /CNW/ - In recognition of World Contraception Day (WCD) on September 26, Org...

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands — Oct 8th, 2024

Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women...

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024 — Oct 9th, 2024

Company estimates $51 million of milestone expense in the third quarter JERSEY CITY, N.J., October 09, 2024--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its third quarter 2024 financial results on October 31, 2024, prior...

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands — Oct 8th, 2024

Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women...

Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner — Oct 9th, 2024

Organon (OGN) has been on a downward spiral lately with significant selling pressure. After declining 9.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the com...

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands — Oct 8th, 2024

Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women...

Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner — Oct 9th, 2024

Organon (OGN) has been on a downward spiral lately with significant selling pressure. After declining 9.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the com...